These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
379 related articles for article (PubMed ID: 20632403)
21. Risk of concurrent bacterial infection in preterm infants hospitalized due to respiratory syncytial virus infection. Resch B; Gusenleitner W; Mueller WD Acta Paediatr; 2007 Apr; 96(4):495-8. PubMed ID: 17326757 [TBL] [Abstract][Full Text] [Related]
22. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada. Paes B; Steele S; Janes M; Pinelli J Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698 [TBL] [Abstract][Full Text] [Related]
23. Respiratory syncytial virus-related bronchiolitis in Puerto Rico. Molinari Such M; García I; García L; Puig G; Pedraza L; Marín J; Valcárcel M P R Health Sci J; 2005 Jun; 24(2):137-40. PubMed ID: 16116931 [TBL] [Abstract][Full Text] [Related]
24. [Perinatal history and hospitalization for bronchiolitis. A comparison with the impact-RSV Study Group]. Bonillo Perales A ; DíezDelgado Rubio J ; Ortega Montes A ; Infante Márquez P ; Jiménez Liria M ; Batlles Garrido J ; López Muñoz J An Esp Pediatr; 2000 Dec; 53(6):527-32. PubMed ID: 11148149 [TBL] [Abstract][Full Text] [Related]
25. Respiratory syncytial virus-associated lower respiratory tract infection in under-5-year-old children in a rural community of central Thailand, a population-based study. Suwanjutha S; Sunakorn P; Chantarojanasiri T; Siritantikorn S; Nawanoparatkul S; Rattanadilok Na Bhuket T; Teeyapaiboonsilpa P; Preutthipan A; Sareebutr W; Puthavathana P J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1111-9. PubMed ID: 12549784 [TBL] [Abstract][Full Text] [Related]
26. Respiratory syncytial virus risk factors in late preterm infants. Lanari M; Silvestri M; Rossi GA J Matern Fetal Neonatal Med; 2009; 22 Suppl 3():102-7. PubMed ID: 19925369 [TBL] [Abstract][Full Text] [Related]
27. Predictive value of the respiratory syncytial virus risk-scoring tool in the term infant in Canada. Paes B; Cole M; Latchman A; Pinelli J Curr Med Res Opin; 2009 Sep; 25(9):2191-6. PubMed ID: 19604126 [TBL] [Abstract][Full Text] [Related]
28. Trends in chronologic age and infant respiratory syncytial virus hospitalization: an 8-year cohort study. Fryzek JP; Martone WJ; Groothuis JR Adv Ther; 2011 Mar; 28(3):195-201. PubMed ID: 21327753 [TBL] [Abstract][Full Text] [Related]
29. Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity. Lanari M; Giovannini M; Giuffré L; Marini A; Rondini G; Rossi GA; Merolla R; Zuccotti GV; Salvioli GP; Pediatr Pulmonol; 2002 Jun; 33(6):458-65. PubMed ID: 12001280 [TBL] [Abstract][Full Text] [Related]
30. Acute bronchiolitis in infancy as risk factor for wheezing and reduced pulmonary function by seven years in Akershus County, Norway. Fjaerli HO; Farstad T; Rød G; Ufert GK; Gulbrandsen P; Nakstad B BMC Pediatr; 2005 Aug; 5():31. PubMed ID: 16109158 [TBL] [Abstract][Full Text] [Related]
31. Respiratory syncytial virus-positive bronchiolitis in hospitalized infants is associated with thrombocytosis. Bilavsky E; Yarden-Bilavsky H; Shouval DS; Fisch N; Garty BZ; Ashkenazi S; Amir J Isr Med Assoc J; 2010 Jan; 12(1):39-41. PubMed ID: 20450128 [TBL] [Abstract][Full Text] [Related]
32. Risk factors for recurrent wheezing following acute bronchiolitis: a 12-month follow-up. Cifuentes L; Caussade S; Villagrán C; Darrigrande P; Bedregal P; Valdivia G; Sánchez I Pediatr Pulmonol; 2003 Oct; 36(4):316-21. PubMed ID: 12950045 [TBL] [Abstract][Full Text] [Related]
33. Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. Blanken M; Rovers M; Sanders E; Bont L Contemp Clin Trials; 2012 Nov; 33(6):1287-92. PubMed ID: 22820319 [TBL] [Abstract][Full Text] [Related]
34. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173 [TBL] [Abstract][Full Text] [Related]
35. Healthcare resource utilisation and costs in infants with confirmed respiratory syncytial virus infections: a national population cohort study. Han HJ; Ryu D; Kim JY; Jang S; Suh HS BMC Infect Dis; 2024 Oct; 24(1):1152. PubMed ID: 39396944 [TBL] [Abstract][Full Text] [Related]
37. Impact of RSV: implications for managed care. Makari D; Hoopes JM; White N Manag Care; 2009 Jan; 18(1 Suppl 2):2-7. PubMed ID: 19230529 [TBL] [Abstract][Full Text] [Related]
38. U-EPX levels and wheezing in infants and young children with and without RSV bronchiolitis. Kristjánsson S; Wennergren D; Eriksson B; Thórarinsdóttir H; Wennergren G Respir Med; 2006 May; 100(5):878-83. PubMed ID: 16198099 [TBL] [Abstract][Full Text] [Related]
39. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Sigurs N; Bjarnason R; Sigurbergsson F; Kjellman B; Björkstén B Pediatrics; 1995 Apr; 95(4):500-5. PubMed ID: 7700748 [TBL] [Abstract][Full Text] [Related]